Kevin M. Kalinsky, MD, looks forward to the new data concerning the population of patients with hormone receptor–positive, HER2-negative (HR+/HER2-) breast cancer which are being presented at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS). There will be an update from the ongoing phase 3 TAILORx trial, looking at individualized treatment options for patients; as well as data on race, treatment outcome disparities, and quality-of-life measures from the phase 3 RxPONDER study.
In the setting of metastatic HR+/HER2- breast cancer, Dr Kalinsky expects exciting and positive data on novel agents in development, including the phase 3 CAPItello-291 trial, assessing the efficacy of capivasertib and fulvestrant for patients with aromatase inhibitor–resistant HR+/HER2- advanced breast cancer. In addition, there will be a readout of the further analysis of the overall survival data from the phase 3 TROPiCS-02 study, looking at the benefit of the antibody-drug conjugate sacituzumab govitecan in the endocrine-resistant patient population.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SABCS 2022: New HR+/HER2- Breast Cancer Data Expected - Medscape - Dec 19, 2022.
Comments